{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T21:08:20Z","timestamp":1777496900905,"version":"3.51.4"},"reference-count":28,"publisher":"SAGE Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CH"],"published-print":{"date-parts":[[2021,12,17]]},"abstract":"<jats:p>BACKGROUND: Interstitial cystitis (IC) is a prevalent and debilitating chronic inflammatory disease of the urinary bladder. Currently there are no fully effective therapeutic agents available, in part due to the still obscure pathogenesis of IC. Lipopolysaccharide (LPS) also known as endotoxin from Gram negative bacteria elicits IC in mice and has formed the basis of model systems for investigation. Excess free iron plays an important role in inflammation through generation of reactive oxygen species (ROS). The novel iron chelator DIBI has been shown to sequester excess free iron and dampen excess inflammatory responses to systemic LPS administration and also to Gram negative bacterial infections. OBJECTIVE: The overall objective of this study was to evaluate the effects of DIBI on LPS induced IC in mice. Leukocyte activation, endothelial adhesion and functional capillary density were assessed by intravital microscopy of the bladder microcirculation following a single intravesical LPS administration with or without intravesical DIBI treatment. Clinical IC symptoms were also assessed through behavioral and pain threshold force measurements. METHODS: Four groups of female BALB\/c mice (n\u200a=\u200a5\u20136\/group) were randomized in this study: control group, IC group without therapy, IC group with DIBI therapy and control group with DIBI therapy. The groups were examined using intravital microscopy (IVM) of the bladder for leukocyte-endothelial interactions (adherent leukocytes, temporarily interacting leukocytes) and functional capillary density (FCD). A modified behavioral score by Boucher et al. and Von-Frey-Aesthesiometry were used to evaluate key behavioral indices related to pain and visceral pain perception. RESULTS: LPS introduced intravesically induced an early (\u22642h) inflammation of the bladder evidenced by leukocyte activation and adhesion to bladder capillary walls. Intravesical DIBI therapy of mice 30min following LPS administration and assessed after 1.5h treatment showed a significant decrease in the number of adherent leukocytes compared to IC animals without DIBI treatment. DIBI treated mice showed a significantly lowered increase in behavioral distress scores compared to IC mice without therapy. Untreated IC mice exhibited a significantly decreased threshold force value for evoked pain response and DIBI treatment improved the threshold pain response. A significant inverse correlation was found for the two pain and suffering evaluation methods results. CONCLUSION: DIBI reduced inflammatory endothelial leukocyte adhesion and key indices related to pain and suffering over those observed in untreated IC mice. Our findings suggest a potential therapeutic role for DIBI for IC treatment.<\/jats:p>","DOI":"10.3233\/ch-201078","type":"journal-article","created":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T13:30:51Z","timestamp":1640093451000},"page":"395-406","source":"Crossref","is-referenced-by-count":5,"title":["Anti-inflammatory iron chelator, DIBI, reduces leukocyte-endothelial adhesion and clinical symptoms of LPS-induced interstitial cystitis in mice"],"prefix":"10.1177","volume":"79","author":[{"given":"Georg","family":"Hagn","sequence":"first","affiliation":[{"name":"Department of Anesthesia, Pain Management and Perioperative Medicine, Dalhousie University, Halifax, NS, Canada"},{"name":"Department of Pharmacology, Dalhousie University, Halifax, NS, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce","family":"Holbein","sequence":"additional","affiliation":[{"name":"Department of Microbiology & Immunology, Dalhousie University, Halifax, NS, Canada"},{"name":"Chelation Partners Inc., The Labs at Innovacorp, Life Sciences Research Institute, Halifax, NS, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Anesthesia, Pain Management and Perioperative Medicine, Dalhousie University, Halifax, NS, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Lehmann","sequence":"additional","affiliation":[{"name":"Department of Anesthesia, Pain Management and Perioperative Medicine, Dalhousie University, Halifax, NS, Canada"},{"name":"Department of Pharmacology, Dalhousie University, Halifax, NS, Canada"},{"name":"Department of Microbiology & Immunology, Dalhousie University, Halifax, NS, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","reference":[{"key":"10.3233\/CH-201078_ref1","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0022-5347(05)67495-2","article-title":"Cyclophosphamide-induced in freely-moving conscious rats: Behavioral approach to a new model of visceral pain","volume":"164","author":"Boucher","year":"2000","journal-title":"J Urol"},{"key":"10.3233\/CH-201078_ref2","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/nau.20687","article-title":"Status of international consensus on interstitial cystitis\/bladder pain syndrome\/painful bladder syndrome: 2008 snapshot","volume":"28","author":"Hanno","year":"2009","journal-title":"Neurourol Urodyn"},{"key":"10.3233\/CH-201078_ref3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/iju.12308","article-title":"Bladder afferent hyperexcitability in bladder pain syndrome\/interstitial cystitis","volume":"21","author":"Yoshimura","year":"2014","journal-title":"Int J Urol"},{"key":"10.3233\/CH-201078_ref4","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1007\/s40265-015-0504-9","article-title":"The Challenges of Interstitial Cystitis: Current Status and Future Prospects","volume":"75","author":"Belknap","year":"2015","journal-title":"Drugs"},{"key":"10.3233\/CH-201078_ref5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1177\/1756287211398255","article-title":"Role of inflammation in bladder function and interstitial cystitis","volume":"3","author":"Grover","year":"2011","journal-title":"Ther Adv Urol"},{"key":"10.3233\/CH-201078_ref6","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1007\/s00192-012-1699-x","article-title":"Risk factors that affect the treatment of interstitial cystitis using intravesical therapy with a dimethyl sulfoxide cocktail","volume":"23","author":"Hung","year":"2012","journal-title":"Int Urogynecol J"},{"key":"10.3233\/CH-201078_ref7","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1007\/s00192-016-3232-0","article-title":"Long-term outcomes of intravesical dimethyl sulfoxide\/heparin\/hydrocortisone therapy for interstitial cystitis\/bladder pain syndrome","volume":"28","author":"Lim","year":"2017","journal-title":"Int Urogynecol J"},{"key":"10.3233\/CH-201078_ref8","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1007\/s11255-019-02248-5","article-title":"A new look at the etiology of interstitial cystitis\/bladder pain syndrome: extraordinary cultivations","volume":"51","author":"Aydogan","year":"2019","journal-title":"Int Urol Nephrol"},{"key":"10.3233\/CH-201078_ref9","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/j.urology.2007.12.091","article-title":"Urinary Tract Infection and Inflammation at Onset of Interstitial Cystitis\/Painful Bladder Syndrome","volume":"71","author":"Warren","year":"2008","journal-title":"Urology"},{"key":"10.3233\/CH-201078_ref10","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41579-020-0324-0","article-title":"Urinary tract infections: microbial pathogenesis, host\u2013pathogen interactions and new treatment strategies","volume":"18","author":"Klein","year":"2020","journal-title":"Nat Rev Microbiol"},{"key":"10.3233\/CH-201078_ref11","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s002400000114","article-title":"Determination of mouse bladder inflammatory response to E. coli lipopolysaccharide","volume":"28","author":"Jerde","year":"2000","journal-title":"Urol Res"},{"key":"10.3233\/CH-201078_ref12","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ejphar.2014.02.013","article-title":"Evaluation of selective cannabinoid CB1 and CB2 receptor agonists in a mouse model of lipopolysaccharide-induced interstitial cystitis","volume":"729","author":"Tambaro","year":"2014","journal-title":"Eur J Pharmacol"},{"key":"10.3233\/CH-201078_ref13","doi-asserted-by":"publisher","DOI":"10.3233\/CH-209207"},{"key":"10.3233\/CH-201078_ref14","doi-asserted-by":"publisher","first-page":"283","DOI":"10.3390\/antibiotics9060283","article-title":"Iron chelation in murine models of systemic inflammation induced by gram-positive and gram-negative toxins","volume":"9","author":"Fokam","year":"2020","journal-title":"Antibiotics"},{"key":"10.3233\/CH-201078_ref15","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1159\/000496089","article-title":"Iron Chelation as Novel Treatment for Interstitial Cystitis","volume":"103","author":"Hagn","year":"2019","journal-title":"Pharmacology"},{"key":"10.3233\/CH-201078_ref16","doi-asserted-by":"publisher","first-page":"4239","DOI":"10.3390\/molecules24234239","article-title":"Experimental Cannabinoid 2 Receptor Activation by Phyto-Derived and Synthetic Cannabinoid Ligands in LPS-Induced Interstitial Cystitis in Mice","volume":"24","author":"Berger","year":"2019","journal-title":"Molecules"},{"key":"10.3233\/CH-201078_ref17","doi-asserted-by":"publisher","first-page":"6573","DOI":"10.1038\/s41598-018-24833-x","article-title":"Sub-noxious Intravesical Lipopolysaccharide Triggers Bladder Inflammation and Symptom Onset in A Transgenic Autoimmune Cystitis Model: A MAPP Network Animal Study","volume":"8","author":"Kogan","year":"2018","journal-title":"Sci Rep"},{"key":"10.3233\/CH-201078_ref18","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/694312"},{"key":"10.3233\/CH-201078_ref19","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1097\/ACO.0b013e328328d1b6","article-title":"The impact of the glycocalyx on microcirculatory oxygen distribution in critical illness","volume":"22","author":"Chappell","year":"2009","journal-title":"Curr Opin Anaesthesiol"},{"key":"10.3233\/CH-201078_ref20","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.biochi.2018.06.014","article-title":"Experimental human endotoxemia as a model of systemic inflammation","volume":"159","author":"van Lier","year":"2019","journal-title":"Biochimie"},{"key":"10.3233\/CH-201078_ref21","doi-asserted-by":"publisher","first-page":"1632099","DOI":"10.1080\/20013078.2019.1632099","article-title":"Analysis of the Escherichia coli extracellular vesicle proteome identifies markers of purity and culture conditions","volume":"8","author":"Hong","year":"2019","journal-title":"J Extracell Vesicles"},{"key":"10.3233\/CH-201078_ref22","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1039\/c8md00192h","article-title":"DIBI, a 3-hydroxypyridin- 4-one chelator iron-binding polymer with enhanced antimicrobial activity","volume":"9","author":"Ang","year":"2018","journal-title":"Medchemcomm"},{"key":"10.3233\/CH-201078_ref23","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s10534-020-00253-1","article-title":"Enhanced Fe3+binding through cooperativity of 3- hydroxypyridin-4-one groups within a linear co-polymer: wrapping effect leading to superior antimicrobial activity","volume":"33","author":"Gumbau-Brisa","year":"2020","journal-title":"BioMetals"},{"key":"10.3233\/CH-201078_ref24","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02353-19"},{"key":"10.3233\/CH-201078_ref25","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00855-19"},{"key":"10.3233\/CH-201078_ref26","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1186\/cc2894","article-title":"Bench-to-bedside review: Sepsis is a disease of the microcirculation","volume":"8","author":"Spronk","year":"2004","journal-title":"Crit Care"},{"key":"10.3233\/CH-201078_ref27","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1097\/00003246-199502000-00011","article-title":"Microvascular function and rheologic changes in hyperdynamic sepsis","volume":"23","author":"Astiz","year":"1995","journal-title":"Crit Care Med"},{"key":"10.3233\/CH-201078_ref28","doi-asserted-by":"publisher","first-page":"241","DOI":"10.3233\/CH-179205","article-title":"Anti-inflammatory effects of a novel iron chelator, DIBI, in experimental sepsis","volume":"67","author":"Thorburn","year":"2017","journal-title":"Clin Hemorheol Microcirc"}],"container-title":["Clinical Hemorheology and Microcirculation"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/CH-201078","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T15:05:10Z","timestamp":1777388710000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.medra.org\/servlet\/aliasResolver?alias=iospress&doi=10.3233\/CH-201078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,17]]},"references-count":28,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.3233\/ch-201078","relation":{},"ISSN":["1386-0291","1875-8622"],"issn-type":[{"value":"1386-0291","type":"print"},{"value":"1875-8622","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,17]]}}}